BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CP-383 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CP-383\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07030257-2438@assetmemo.bio
DTSTAMP:20261121T005855Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:CP-383: Phase 1/2 readout est. (NCT07030257)
DESCRIPTION:CP-383\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 of CP-383 in Patients With Advanced or Metastatic Solid Tumors\nEstimated 
 primary completion: 15 August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cp-383#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07030257
URL:https://assetmemo.bio/drug/cp-383#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
